Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charu Aggarwal

Showing results (1-10 of 198) with videos related to

Pageof 20
Sort By:
Annals of Palliative Medicine|April 6, 2015
Targeted therapy for lung cancer: present and futureCharu Aggarwal
Immunotherapy|September 9, 2016
DNA-based immunotherapy for HPV-associated head and neck cancerCharu Aggarwal
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2022
Aumolertinib in <i>EGFR</i>-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease <i>Access</i>?Charu Aggarwal, Bishal Gyawali
Cancer Journal (Sudbury, Mass.)|December 10, 2020
Immunotherapy for Lung Cancer-Improving Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer With ImmunotherapyLova Sun, Charu Aggarwal
Oncotargets and Therapy|July 10, 2010
Rational use of cetuximab in the treatment of advanced non-small cell lung cancerCharu Aggarwal, Hossein Borghaei
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 3, 2022
Pembrolizumab Administration Frequency, Dose Exposure, and Toxicity: Is Switching Safe?Giannis Mountzios, Charu Aggarwal
Cancer Discovery|August 4, 2025
Toward Response-Adaptive Therapy in Locally Advanced NSCLC: Integrating ctDNA and Radiomics for Risk StratificationValsamo Anagnostou, Charu Aggarwal
The Oncologist|April 15, 2017
Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint DesignCharu Aggarwal, Hossein Borghaei
The New England Journal of Medicine|November 3, 2006
Case 24-2006: a woman with hypotension after an overdose of amlodipineCharu Aggarwal, Sameer Gupta
Cancer Discovery|December 5, 2018
Molecular Characterization of Malignant Mesothelioma: Time for New Targets?Charu Aggarwal, Steven M Albelda
Pageof 20

Showing results (1-10 of 198) with videos related to

Sort By:
Pageof 20
Annals of Palliative Medicine|April 6, 2015
Targeted therapy for lung cancer: present and futureCharu Aggarwal
Immunotherapy|September 9, 2016
DNA-based immunotherapy for HPV-associated head and neck cancerCharu Aggarwal
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2022
Aumolertinib in <i>EGFR</i>-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease <i>Access</i>?Charu Aggarwal, Bishal Gyawali
Cancer Journal (Sudbury, Mass.)|December 10, 2020
Immunotherapy for Lung Cancer-Improving Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer With ImmunotherapyLova Sun, Charu Aggarwal
Oncotargets and Therapy|July 10, 2010
Rational use of cetuximab in the treatment of advanced non-small cell lung cancerCharu Aggarwal, Hossein Borghaei
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 3, 2022
Pembrolizumab Administration Frequency, Dose Exposure, and Toxicity: Is Switching Safe?Giannis Mountzios, Charu Aggarwal
Cancer Discovery|August 4, 2025
Toward Response-Adaptive Therapy in Locally Advanced NSCLC: Integrating ctDNA and Radiomics for Risk StratificationValsamo Anagnostou, Charu Aggarwal
The Oncologist|April 15, 2017
Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint DesignCharu Aggarwal, Hossein Borghaei
The New England Journal of Medicine|November 3, 2006
Case 24-2006: a woman with hypotension after an overdose of amlodipineCharu Aggarwal, Sameer Gupta
Cancer Discovery|December 5, 2018
Molecular Characterization of Malignant Mesothelioma: Time for New Targets?Charu Aggarwal, Steven M Albelda
Pageof 20